Pharming Group Q4 Earnings Call Highlights

3 days ago 5

MarketBeat

Thu, March 12, 2026 astatine 9:48 AM CDT 9 min read

Pharming Group logo

Pharming closed 2025 with full gross up 27% to €376.1m, returned to operating profitability with an adjusted operating nett of €36.4m, improved operating currency travel to €54.7m, and held €181.1m successful currency and marketable securities contempt a €68m acquisition.
Commercial momentum: RUCONEST grew ~26% successful 2025 portion Joenja roseate ~29% for the twelvemonth (Q4 +53%), with Joenja Q4 gross of $19.8m, full-year $58m and 120 U.S. patients connected paid therapy; absorption expects Joenja maturation to accelerate successful 2026, ~70–75% driven by the U.S.
2026 guidance and pipeline: absorption reiterated gross guidance of €405–425m and operating expenses of €330–335m (including >€60m R&D); regulatory risks see an FDA CRL for pediatric Joenja with a Type A gathering scheduled, near-term EU/JP decisions expected, portion leniolisib PoC readouts are owed H2 2026 and napazimone pivotal information are targeted successful 2027.
Interested successful Pharming Group N.V. Sponsored ADR? Here are 5 stocks we similar better.

Pharming Group (NASDAQ:PHAR) reported what absorption described arsenic a beardown decorativeness to 2025, highlighting double-digit gross growth, a instrumentality to operating profitability, and expanding commercialized traction for some RUCONEST and Joenja during its fourth-quarter and full-year 2025 net call.

Chief Executive Officer Fabrice Chouraqui said full revenues grew 15% successful the 4th fourth of 2025 and 27% for the afloat year, supported by maturation successful RUCONEST and Joenja and “disciplined outgo management.” The institution delivered $26 cardinal of operating nett successful 2025 compared with an operating nonaccomplishment successful 2024, according to Chouraqui.

→ Microsoft Positioned to Win AI Race With Dual-Model Strategy

Chief Financial Officer Kenneth Lynard provided further detail, reporting fourth-quarter gross of EUR 106.5 million, up 15% versus the prior-year period. For the afloat year, Pharming posted EUR 376.1 million successful full revenue, up 27% year-over-year, and said gross borderline was unchangeable astatine astir 88%, contempt a EUR 5 cardinal Joenja income milestone recorded successful outgo of goods sold during the 4th quarter.

Lynard said operating expenses accrued to EUR 311.3 million successful 2025. Excluding EUR 4.1 million of one-off restructuring costs tied to a G&A simplification programme announced successful October, operating expenses were EUR 307.2 million, which helium said was wrong the company’s erstwhile guidance scope of EUR 304 cardinal to EUR 308 million. He added that excluding EUR 29.7 million of Abliva-related expenses, operating expenses were up lone 2% connected a like-for-like basis.

Read Entire Article